This page shows the latest subcutaneous injection news and features for those working in and with pharma, biotech and healthcare.
The treatment is administered as a subcutaneous injection four times per year after two starter doses for the treatment of paediatric patients aged six years and older with active PsA.
Roche has announced results from its phase 3 IMscin001 study assessing Tecentriq (atezolizumab) as a subcutaneous formulation. ... The investigational subcutaneous formulation combines Tecentriq with Halozyme Therapeutics’ Enhanze drug delivery
Saphnelo is available as an infusion but AstraZeneca is running a phase 3 trial to assess the antibody as a subcutaneous injection.
New administration offers same efficacy as subcutaneous injection. The European Commission (EC) has approved a new intramuscular (IM) injection route of administration for Biogen’s Plegridy for the treatment of ... In 2014, Plegridy was initially
Based on the phase 2 study findings to date, marstacimab may have the potential to offer improved bleed control via subcutaneous injection and potentially eliminate the need for prophylactic factor replacement,
In these trials, Leqvio demonstrated LDL-C reduction of up to 52% with two doses per year administered as a subcutaneous injection, following an initial dose and one at three months,
More from news
Approximately 1 fully matching, plus 97 partially matching documents found.
It’s given as a subcutaneous injection that takes less than a minute to deliver every two weeks, around 75% fewer injections than other products for HAE prevention. ... Injection volumes are lower, it can be taken weekly as well as monthly and can be
Growth hormone treatment (GHT) is only available on prescription and is given as a subcutaneous injection (directly under the skin). ... complete, partial, missed) of each injection, and uploads this data wirelessly from the patients’ homes to the
Arsia has a proprietary viscosity reducing technology and know-how to enable the development of high concentration formulations of biologics that can be administered by subcutaneous injection rather than intravenously. ... Invossa, cell-mediated gene
cells. The product has been submitted to the EMA following a phase III trial showing safety and efficacy of a single injection in the treatment of complex peri-anal fistulas, and ... The presentation is subcutaneous injection in both indications, leaving
At the moment, biologics are generally delivered by intravenous or subcutaneous injection, which is effective but not desirable for patients, particularly for chronic conditions.
More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.
drug delivery platform, which allows therapeutic drug levels to be maintained for five days with a single subcutaneous injection.
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Welcome to the Difference Collective – a healthcare communications team of 80+ talented experts who Deliver Differently. We’re purpose-built around...